JP2025503511A5 - - Google Patents
Info
- Publication number
- JP2025503511A5 JP2025503511A5 JP2024538652A JP2024538652A JP2025503511A5 JP 2025503511 A5 JP2025503511 A5 JP 2025503511A5 JP 2024538652 A JP2024538652 A JP 2024538652A JP 2024538652 A JP2024538652 A JP 2024538652A JP 2025503511 A5 JP2025503511 A5 JP 2025503511A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- her2
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163294367P | 2021-12-28 | 2021-12-28 | |
| US63/294,367 | 2021-12-28 | ||
| PCT/IB2022/062797 WO2023126822A1 (en) | 2021-12-28 | 2022-12-27 | Combination of antibody-drug conjugate and rasg12c inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503511A JP2025503511A (ja) | 2025-02-04 |
| JP2025503511A5 true JP2025503511A5 (https=) | 2026-01-05 |
Family
ID=84943594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538652A Pending JP2025503511A (ja) | 2021-12-28 | 2022-12-27 | 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250161305A1 (https=) |
| EP (1) | EP4456899A1 (https=) |
| JP (1) | JP2025503511A (https=) |
| CN (1) | CN118434422A (https=) |
| TW (1) | TW202333800A (https=) |
| WO (1) | WO2023126822A1 (https=) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| KR102934231B1 (ko) | 2019-03-05 | 2026-03-06 | 아스트라제네카 아베 | 항암제로 유용한 융합 삼환식 화합물 |
| PT3886991T (pt) | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
-
2022
- 2022-12-27 EP EP22843394.2A patent/EP4456899A1/en active Pending
- 2022-12-27 WO PCT/IB2022/062797 patent/WO2023126822A1/en not_active Ceased
- 2022-12-27 JP JP2024538652A patent/JP2025503511A/ja active Pending
- 2022-12-27 US US18/724,593 patent/US20250161305A1/en active Pending
- 2022-12-27 TW TW111150125A patent/TW202333800A/zh unknown
- 2022-12-27 CN CN202280084640.8A patent/CN118434422A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025041725A5 (https=) | ||
| JP2023539715A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2023542066A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| JP2023070678A5 (https=) | ||
| JPWO2020130125A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2010535713A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| JP2023522229A5 (https=) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2008500815A5 (https=) | ||
| JP2019031565A5 (https=) | ||
| JP2015527318A5 (https=) | ||
| JP2018525354A5 (https=) | ||
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| CN120393061A (zh) | 放射性免疫缀合物与dna损伤和修复抑制剂组合疗法 | |
| JP2020526584A5 (https=) | ||
| CN106999606A (zh) | 抗体药物偶联物 | |
| JP2025507817A5 (https=) | ||
| JP2024536881A5 (https=) | ||
| JP2020534300A5 (https=) | ||
| JP2024546605A5 (https=) | ||
| JP2025509266A5 (https=) |